The Opium (Opioid) Addiction drugs in development market research report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Opium (Opioid) Addiction. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued products.
GlobalData tracks 107 drugs in development for Opium (Opioid) Addiction by 89 companies/universities/institutes. The top development phase for Opium (Opioid) Addiction is preclinical with 54 drugs in that stage. The Opium (Opioid) Addiction pipeline has 96 drugs in development by companies and 11 by universities/ institutes. Some of the companies in the Opium (Opioid) Addiction pipeline products market are: Sen-Jam Pharmaceutical, Cessation Therapeutics and BioCorRx.
The key targets in the Opium (Opioid) Addiction pipeline products market include Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1), Kappa Type Opioid Receptor (KOR1 or OPRK or OPRK1), and Delta Type Opioid Receptor (DOR1 or OPRD or OPRD1).
The key mechanisms of action in the Opium (Opioid) Addiction pipeline product include Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1) Agonist with 23 drugs in Filing rejected/Withdrawn. The Opium (Opioid) Addiction pipeline products include 11 routes of administration with the top ROA being Oral and nine key molecule types in the Opium (Opioid) Addiction pipeline products market including Small Molecule, and Conjugate Vaccine.
Opium (Opioid) Addiction overview
Opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers, known as endorphins). This can lead to an inability of the body to stop pain, because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping, and pain in the bones. The predisposing factors include age, a personal history of substance abuse, family history of substance abuse, cigarette dependency, and psychological stress.
For a complete picture of Opium (Opioid) Addiction’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
